Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ganaxolone in Status Epilepticus
NCT04391569Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Mar 2024
- Modality
- Allosteric Modulators
- Countries
- 3
01
Overview
A Phase 3 trial of ganaxolone in status epilepticus (SE), sponsored by Marinus Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT04391569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391569.